CHINA PHARMA HOLDINGS Files 8-K on Feb 23
Ticker: CPHI · Form: 8-K · Filed: Feb 23, 2024 · CIK: 1106644
| Field | Detail |
|---|---|
| Company | China Pharma Holdings, Inc. (CPHI) |
| Form Type | 8-K |
| Filed Date | Feb 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
**CHINA PHARMA HOLDINGS just filed a standard 8-K, nothing major to report yet.**
AI Summary
CHINA PHARMA HOLDINGS, INC. filed an 8-K on February 23, 2024, disclosing information under Regulation FD and regarding financial statements and exhibits. The filing indicates the company's current status and basic identifying information, including its Nevada incorporation and SEC file number 001-34471. No specific financial figures or events like acquisitions or insider trades were detailed in this particular filing.
Why It Matters
This filing provides routine disclosure, ensuring transparency and compliance with SEC regulations for investors tracking CHINA PHARMA HOLDINGS, INC.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure filing and does not indicate any specific new risks or events.
Key Players & Entities
- CHINA PHARMA HOLDINGS, INC. (company) — Registrant
- February 23, 2024 (date) — Date of Report
- Nevada (company) — State of Incorporation
- 001-34471 (company) — Commission File No.
- 73-1564807 (company) — IRS Employer Identification No.
FAQ
What is the exact name of the Registrant as specified in its charter?
The exact name of the Registrant is CHINA PHARMA HOLDINGS, INC.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 23, 2024.
In which state or other jurisdiction is CHINA PHARMA HOLDINGS, INC. incorporated?
CHINA PHARMA HOLDINGS, INC. is incorporated in Nevada.
What is the Commission File Number for CHINA PHARMA HOLDINGS, INC.?
The Commission File Number is 001-34471.
What items of information were disclosed in this 8-K filing?
The items of information disclosed were Regulation FD Disclosure and Financial Statements and Exhibits.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-02-23 16:05:47
Key Financial Figures
- $0.001 — common stock of the Company, par value $0.001 per share, will be converted into one p
Filing Documents
- ea0200603-8k_chinapharma.htm (8-K) — 24KB
- ea0200603ex99-1_chinapharma.htm (EX-99.1) — 6KB
- 0001213900-24-016507.txt ( ) — 204KB
- cphi-20240223.xsd (EX-101.SCH) — 3KB
- cphi-20240223_lab.xml (EX-101.LAB) — 33KB
- cphi-20240223_pre.xml (EX-101.PRE) — 22KB
- ea0200603-8k_chinapharma_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On February 23, 2024, China Pharma Holdings, Inc. (the "Company") issued a press release, included herewith as Exhibit 99.1, announcing that it expects to implement a 1-for-5 reverse stock split effective Wednesday, March 6, 2024, that every 5 shares of the pre-split common stock of the Company, par value $0.001 per share, will be converted into one post-split common stock of the Company, par value $0.001 per share, with trading to begin on a split-adjusted basis at the market open on that day. The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. 99.1 Press Release, dated February 23, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 23, 2024 CHINA PHARMA HOLDINGS, INC. By: /s/ Zhilin Li Name: Title: Zhilin Li President and Chief Executive Officer